Marc Duey bought APRE once, on Dec 10, 2025

Marc Duey is a corporate insider and independent director at Aprea Therapeutics, Inc. (NASDAQ: APRE), where he has served on the Board of Directors since May 2022 and is a member of the Compensation Committee.( He brings over three decades of experience in the pharmaceutical and biotechnology industries and has recently reported multiple insider transactions and equity awards at Aprea, including grants of restricted stock units and stock options as part of his board compensation, as well as open‑market share purchases.(

Duey is the Founder, President, and former CEO of ProMetrics Inc., a firm focused on data and analytics for pharmaceutical markets, and previously founded DuWest Research, an international management consulting firm serving diagnostic and biotechnology companies.( He is also a managing partner at Duce Management, LLC, a venture investment vehicle through which he chairs or serves on the boards of several life sciences companies, including Felicitex Therapeutics, Adipoligo Health Sciences, TarMeta Biosciences, and Atrin Pharmaceuticals.( Beyond his corporate roles, Duey serves on the Board of Trustees of International House Philadelphia and the Leadership Council of The Wistar Institute, and is an active member of ASCO, AACR, AAPS, and LES.( He holds a B.S. and M.S. in science from the University of Ottawa and an M.B.A. from the Ivey Business School at Western University in London, Canada, and is also described in professional profiles as a serial entrepreneur and venture investor who teaches marketing and pharmaceutical product development as an adjunct professor at West Chester University.(

Written by Perplexity from public sources.